BiP AP通气联合呼吸兴奋剂治疗慢性阻塞性肺疾病合并肺性脑病的临床研究

Clinical study on BiPAP combined with respiratory stimulant in the treatment of patients with pulmonary encephalopathy and COPD

目的:探讨无创双水平呼吸道正压通气(Bi-level positive airway pressure,BiPAP)联合呼吸兴奋剂+醒脑静治疗慢性阻塞性肺疾病(COPD)合并肺性脑病的临床疗效。方法:将66例COPD合并肺性脑病患者随机分成三组,每组各22例,在BiPAP基础上分别联合纳洛酮+尼可刹米+醒脑静治疗、纳洛酮+醒脑静治疗和纳洛酮治疗,比较三种治疗方法的临床疗效。结果:BiPAP联合呼吸兴奋剂(纳洛酮+尼可刹米)+醒脑静有效率为90.9%,并且在症状改善时间及动脉血气分析结果显著好于其他两组(P<0.05)。结论:BiPAP与呼吸兴奋剂及醒脑静联用,效果明显,值得临床推广应用。

Objective： To evaluate the effect of BiPAP combined with respiratory stimulant and Xingnaojing in the treatment of patients with pulmonary encephalopathy and COPD.Methods： 66 patients with pulmonary encephalopathy and COPD were selected to divide into three groups and each for 22 cases,patients in group A were given BiPAP plus Naloxone,Nikethamide and Xingnaojing;Group B was given BiPAP plus Naloxone and Xingnaojing;Group C was given BiPAP plus Naloxone.Clinical effects of the three methods were compared.Results： The efficient of the method which used BiPAP plus Naloxone,Nikethamide and Xingnaojing was 90.9%,and its effect of blood gas analysis was better than that of the other two groups（P0.05）.Conclusion： The method of BiPAP plus respiratory stimulant and Xingnaojing has a significant effect,and it is worth to promote.